Taltz Injection, Solution
Product Images NDC 0002-7724

26 FDA label images from Eli Lilly And Company · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Taltz (NDC 0002-7724). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Ifu 30 Min Clock)

Figure (Ifu 30 Min Clock)
An illustration of a clock showing 30 minutes, likely indicating a time interval or waiting period related to the product.*
FDA Label Image

Figure (Ifu Injection Sites)

Figure (Ifu Injection Sites)
An instructional diagram showing preferred subcutaneous injection sites on the human body for TALTZ (ixekizumab) injection. The highlighted areas include the abdomen, front thighs, and the back of the upper arms, illustrated on both front and back views of a human figure.*
FDA Label Image
FDA Label Image

Taltz Ai Ifu 1 V2

Taltz Ai Ifu 1 V2
An illustrated diagram of a TALTZ (ixekizumab) pre-filled injection pen, displaying the device with a white and green color scheme and a transparent section showing the liquid inside. The pen is designed for subcutaneous injection and includes visual indicators on the body of the device.*
FDA Label Image

Taltz Ai Ifu 2 V2

Taltz Ai Ifu 2 V2
An instructional diagram of a TALTZ (ixekizumab) injection pen showing labeled parts including the injection button at the top, lock ring with lock/unlock symbols on the side, a clear medicine-filled section, a clear base, and a detachable twist-off base cap exposing the needle end at the bottom. The diagram illustrates the structure and components of the subcutaneous injection device.*
FDA Label Image

Taltz Ai Ifu 3 V3

Taltz Ai Ifu 3 V3
An instructional illustration showing a hand holding a TALTZ (ixekizumab) injection pen. The diagram highlights the location of the expiration date on the pen, indicated by an arrow and a red circle around the blacked-out date area.*
FDA Label Image

Taltz Ai Ifu 4 V2

Taltz Ai Ifu 4 V2
An instructional illustration showing a hand holding a TALTZ injection pen with a focus on a green dial or cap. The diagram highlights a rotational arrow near the dial, indicating the direction to turn, accompanied by lock and unlock icons to guide proper usage of the injection device.*
FDA Label Image

Taltz Ai Ifu 5 V3

Taltz Ai Ifu 5 V3
Instructional illustration showing a hand holding an injection pen administering a subcutaneous injection into the thigh area. The image demonstrates proper injection technique for a solution dosage form, likely representing the TALTZ (ixekizumab) injection.*
FDA Label Image

Taltz Ai Ifu 6 V3

Taltz Ai Ifu 6 V3
An instructional illustration depicting how to prepare an injection using a TALTZ prefilled syringe. The image shows a hand removing a cap from the syringe, and a close-up of the syringe window indicating the locked and unlocked positions of the device.*
FDA Label Image

Taltz Ai Ifu 7 V4

Taltz Ai Ifu 7 V4
An instructional illustration showing the proper use of a TALTZ (ixekizumab) prefilled injection syringe. The image demonstrates pressing the syringe against the skin, indicated by a "Click" sound, with a labeled close-up highlighting the gray plunger. A timer icon showing 10 seconds suggests how long to hold the syringe during injection.*
FDA Label Image

Taltz Ai Ifu 8 V2

Taltz Ai Ifu 8 V2
An instructional illustration showing a hand disposing of a prefilled syringe into a red sharps container, emphasizing safe injection waste disposal.*
FDA Label Image

Taltz Carton Ai 022 05

Taltz Carton Ai 022 05
Packaging label for TALTZ 80 mg/mL injection, a subcutaneous solution of ixekizumab by Eli Lilly and Company. The label includes a depiction of a single-dose prefilled autoinjector and states the package contains 1 x 1 mL single-dose autoinjector. Storage instructions and regulatory information are also displayed.*
FDA Label Image

Taltz Carton Pfs 025 05

Taltz Carton Pfs 025 05
Box packaging label for TALTZ 80 mg/mL injection, containing 1 single-dose prefilled syringe for subcutaneous use. The label features the drug's generic name ixekizumab, dosage form as injection, and manufacturer Eli Lilly and Company. It includes storage instructions, barcode, and a picture of the prefilled syringe.*
FDA Label Image

Figure (Taltz Pfsi Ifu 1)

Figure (Taltz Pfsi Ifu 1)
An illustration of a syringe-like injection device, featuring a transparent barrel, a white flange with finger grips, and a green plunger handle designed for subcutaneous injection.*
FDA Label Image

Figure (Taltz Pfsi Ifu 2)

Figure (Taltz Pfsi Ifu 2)
An instructional diagram of a prefilled syringe assembly showing labeled parts including thumb pad, green plunger rod, finger grips, gray syringe plunger, syringe body with medicine, needle, and needle cap. The syringe is intended for subcutaneous injection of the medication.*
FDA Label Image

Figure (Taltz Pfsi Ifu 3)

Figure (Taltz Pfsi Ifu 3)
An instructional illustration showing a hand holding a syringe labeled with an arrow pointing to an area indicating the location of the syringe's expiration date. The syringe is shown with a clear barrel and a green plunger, demonstrating where to find the expiration date on the injection device.*
FDA Label Image

Figure (Taltz Pfsi Ifu 4)

Figure (Taltz Pfsi Ifu 4)
An instructional illustration showing two hands preparing a syringe with a needle cap. The right hand is removing the needle cap from the syringe, indicated by a red arrow pointing to the right.*
FDA Label Image

Figure (Taltz Pfsi Ifu 5 V2)

Figure (Taltz Pfsi Ifu 5 V2)
An instructional diagram showing a hand pinching the skin with two fingers and red arrows indicating the direction of the pinch. The illustration appears designed to demonstrate the proper technique for preparing a subcutaneous injection.*
FDA Label Image

Figure (Taltz Pfsi Ifu 6 V2)

Figure (Taltz Pfsi Ifu 6 V2)
An instructional illustration showing a hand administering a subcutaneous injection with a syringe at a 45-degree angle to the skin surface, demonstrating proper injection technique for the TALTZ injection solution.*
FDA Label Image

Figure (Taltz Pfsi Ifu 7 V2)

Figure (Taltz Pfsi Ifu 7 V2)
An illustration showing a hand injecting subcutaneously with a syringe and needle into the skin of an arm. No branding or text is visible in the image.*
FDA Label Image

Figure (Taltz Pfsi Ifu 8 V2)

Figure (Taltz Pfsi Ifu 8 V2)
An instructional illustration showing use of the TALTZ injection pen for subcutaneous administration. The top panel depicts a hand holding the injection pen against the skin with a downward motion indicated by a red arrow. The bottom panel highlights the injection pen components labeled as the green plunger rod and gray syringe plunger.*
FDA Label Image

Figure (Taltz Pfsi Ifu 9)

Figure (Taltz Pfsi Ifu 9)
Illustration showing a hand holding a prefilled syringe with a green plunger, positioning the needle tip above the opening of a red sharps disposal container with a white lid, demonstrating safe injection needle disposal practice.*
FDA Label Image

Figure (Taltz Qr V1)

FDA Label Image

Figure 1 (Taltz Uspi 1 V1)

Figure 1 (Taltz Uspi 1 V1)
A line graph depicting the percent of responders over 24 weeks, comparing TALTZ 80 mg Q4W (subcutaneous injection) treatment with placebo. The x-axis represents time in weeks, and the y-axis shows the percent of responders, illustrating higher response rates for TALTZ compared to placebo over time.*
FDA Label Image

Taltz Uspi 2 V1

Taltz Uspi 2 V1
This is a line graph titled ASAS40 showing the percentage of responders over time in weeks (0 to 16) on the x-axis and percent of responders (0 to 100) on the y-axis. Two data series are compared: TALZ 80 mg Q4W, depicted with triangles and a solid line, and Placebo, depicted with squares and a dotted line, showing increasing responder percentages over time with TALZ having higher response rates.*
FDA Label Image

Taltz Uspi 3 V1

Taltz Uspi 3 V1
A line graph titled ASAS40 showing the percent of responders over time in weeks. It compares TALTZ 80 mg Q4W (four-weekly) treatment with placebo. The TALTZ group is represented by a line with triangles, showing a higher and increasing responder percentage reaching about 35% by week 16. The placebo group is shown with a dotted line and squares, with a lower responder percentage peaking around 20% by week 16.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.